Watching Soligenix; Zacks Small-Cap Research Gives Stock $32 Price Valuation; Says "Model Is Highly Dependent Upon Continued Clinical Success Of The Company's Pipeline And Will Be Adjusted Accordingly Based Upon Future Clinical Results"
Watching Soligenix; Zacks Small-Cap Research Gives Stock $32 Price Valuation; Says "Model Is Highly Dependent Upon Continued Clinical Success Of The Company's Pipeline And Will Be Adjusted Accordingly Based Upon Future Clinical Results"
觀注soligenix; Zacks小型股研究給予股票32美元的估價；表示"該模型高度依賴於公司管線的持續臨床成功，並將根據未來的臨床結果進行相應調整"。
Watching Soligenix; Zacks Small-Cap Research Gives Stock $32 Price Valuation; Says "Model Is Highly Dependent Upon Continued Clinical Success Of The Company's Pipeline And Will Be Adjusted Accordingly Based Upon Future Clinical Results"
觀注soligenix; Zacks小型股研究給予股票32美元的估價；表示"該模型高度依賴於公司管線的持續臨床成功，並將根據未來的臨床結果進行相應調整"。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。